Home
Aarti Pharmalabs Ltd Share Price History
Aarti Pharmalabs Ltd
NSE : 14 Aug, 2025
757.55-32.9 (-4.2%)
Prev Close
790.5
Open Price
793.9
Bid Price (QTY)
-
Offer Price (QTY)
-
Volume
1229473
Today's High / Low
799.0 / 740.8
52 WK High / Low
971.0 / 557.0
Market Price of Aarti Pharmalabs Ltd
1M
1Y
3Y
5Y
Monitoring Aarti Pharmalabs Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.
History Market Price
| Date | Price | Open | High | Low |
|---|
Returns Comparison
1W
1M
3M
6M
1Y
3Y
5Y
10Y
Growth Parameters
| Parameter |  2021 |
|---|---|
| Sales (Cr.) | NaN |
| Sales YoY Gr. | - |
| Adj EPS | -0.18 |
| YoY Gr. | - |
| Net Profit (Cr.) | 0 |
| BVPS | 9.12 |
Key Financial Parameters
| Parameter | 2021 |
|---|---|
| Return on Capital Emp. % | 0 |
| Op. Profit Mgn % | 0 |
| Net Profit Mgn % | 0 |
| Debt to Equity % | 0.09 |
Latest Shareholding
Promoters Holdings Over Time
About Aarti Pharmalabs Ltd
- Aarti Pharmachem Limited, formerly known as Aarti Organics Limited, was incorporated as a Public Limited Company in 2019.
- The Company changed the name from Aarti Organics Limited to Aarti Pharmachem Limited on July 1, 2021.
- The Company is engaged in manufacturer of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine derivatives situated in India.
- It specialise in developing and manufacturing Highly Potent Active Pharmaceutical Ingredients (HPAPIs) critical for various therapeutic segments such as Anti-cancer, Anti-Asthma, Anti-Hypertensive etc. In 2001, the Company commissioned first API manufacturing Unit in Dombivali (Unit 1) and started Xanthine Unit; further it commissioned first API manufacturing Unit 4 in Tarapur for Regulated Markets in 2005; commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tonnes (MT) per month in 2016.
Popular Search
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
